Calamos Advisors LLC Buys Shares of 57,250 BioLife Solutions, Inc. (NASDAQ:BLFS)

Calamos Advisors LLC bought a new position in BioLife Solutions, Inc. (NASDAQ:BLFS - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 57,250 shares of the medical equipment provider's stock, valued at approximately $1,227,000. Calamos Advisors LLC owned approximately 0.12% of BioLife Solutions at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. 1620 Investment Advisors Inc. bought a new position in shares of BioLife Solutions during the 2nd quarter valued at $35,000. GAMMA Investing LLC bought a new stake in shares of BioLife Solutions in the 4th quarter valued at about $41,000. Register Financial Advisors LLC bought a new stake in shares of BioLife Solutions in the 1st quarter valued at about $96,000. State Board of Administration of Florida Retirement System purchased a new stake in BioLife Solutions during the 1st quarter valued at about $229,000. Finally, Price T Rowe Associates Inc. MD grew its position in BioLife Solutions by 10.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 15,129 shares of the medical equipment provider's stock worth $281,000 after acquiring an additional 1,374 shares during the last quarter. 93.24% of the stock is currently owned by institutional investors.

Insider Buying and Selling at BioLife Solutions

In other news, insider Sarah Aebersold sold 3,000 shares of the business's stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $21.03, for a total transaction of $63,090.00. Following the completion of the transaction, the insider now directly owns 61,683 shares of the company's stock, valued at $1,297,193.49. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other BioLife Solutions news, CMO Todd Berard sold 10,000 shares of the firm's stock in a transaction dated Friday, June 14th. The stock was sold at an average price of $20.18, for a total value of $201,800.00. Following the transaction, the chief marketing officer now directly owns 108,894 shares of the company's stock, valued at $2,197,480.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Sarah Aebersold sold 3,000 shares of the business's stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $21.03, for a total value of $63,090.00. Following the sale, the insider now owns 61,683 shares of the company's stock, valued at $1,297,193.49. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 14,844 shares of company stock worth $305,052. Company insiders own 2.20% of the company's stock.

BioLife Solutions Stock Up 2.7 %

BioLife Solutions stock traded up $0.68 on Monday, hitting $25.98. 327,050 shares of the stock traded hands, compared to its average volume of 392,709. BioLife Solutions, Inc. has a 1 year low of $8.92 and a 1 year high of $26.73. The firm has a market cap of $1.20 billion, a P/E ratio of -17.82 and a beta of 1.85. The company has a current ratio of 2.89, a quick ratio of 1.77 and a debt-to-equity ratio of 0.05. The business's fifty day simple moving average is $22.45 and its 200 day simple moving average is $19.97.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on BLFS shares. Craig Hallum raised their target price on shares of BioLife Solutions from $23.00 to $30.00 and gave the stock a "buy" rating in a report on Monday, August 12th. Northland Securities raised their price target on shares of BioLife Solutions from $26.00 to $28.00 and gave the stock an "outperform" rating in a report on Friday, August 9th. StockNews.com raised shares of BioLife Solutions to a "sell" rating in a research note on Friday, May 10th. TD Cowen raised their target price on BioLife Solutions from $20.00 to $26.00 and gave the stock a "buy" rating in a research note on Wednesday, July 17th. Finally, Benchmark raised BioLife Solutions from a "neutral" rating to a "buy" rating and set a $25.00 price target for the company in a research report on Monday, May 13th. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. According to MarketBeat.com, BioLife Solutions currently has an average rating of "Moderate Buy" and a consensus target price of $26.20.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.